VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Chris Recknor, M.D., Chief Operating Officer will host an investment community webcast on Wednesday, May 5, 2021.

Management will provide a full update to its stockholders on Company priorities, including recent COVID-19 initiatives and additional information concerning its active trials in COVID-19, NASH and cancer.

Management will dedicate approximately 60 minutes to address questions submitted online by analysts and investors.

Date: Wednesday, May 5, 2021 Time: 1:00 pm PT / 4:00 pm ET Dial-In: None. Questions:

Prior to the webcast, questions can be submitted online to

During the webcast, questions can be submitted through the webcast link below.

This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at  www.cytodyn.com  under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below webcast link will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until June 5, 2021.

CONTACTS Investors: Michael Mulholland Office: 360.980.8524, ext. 102 mmulholland@cytodyn.com

 
 

Copyright 2021 GlobeNewswire, Inc.